Current clinical trials investigating the use of pharmacological agents for the treatment of NAFLD (Table 1) tend to focus on GLP-1 receptor agonists, SGLT2 inhibitors, or PPAR agonists. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.